Notification regarding unquoted securities - TLX

Oct 4, 2026 at 5:22 PM EDT · Issued by Telix Pharmaceuticals Limited via ASX

Filed with ASX · Oct 4, 2026 at 5:22 PM EDT

On 6ix: 6ix.com/news/notification-regarding-unquoted-securities-tlx-1

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securitiesAppendix 3G - Notification of issue, conversion or payment up of unquoted equity securities1 / 5Announcement SummaryEntity nameTELIX PHARMACEUTICALS LIMITEDDate of this announcementMonday October 05, 2026The...

View Attachment

6ix hasn’t read this filing yet.

Telix Pharmaceuticals Limited on 6ix

Earlier from Telix Pharmaceuticals

Application for quotation of securities - TLXOct 4
Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer ImagingSep 29
FDA Fast Track for BiPASS Pre Biopsy Prostate ImagingSep 29
Change in substantial holdingSep 25
Appendix 3Y Change in Director Interest-D GillSep 25

Later from Telix Pharmaceuticals

Notification of cessation of securities - TLXOct 4
First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)Oct 6
Telix to Host Capital Markets Day in Melbourne on November 4, 2026Oct 9
Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANMOct 14
Telix Reports Third Quarter 2026 Financial PerformanceOct 20

All Telix Pharmaceuticals news releases

Follow Telix Pharmaceuticals into a list and get an email when it puts out news.

Follow Telix Pharmaceuticals